Effectiveness and safety of ticagrelor in acute coronary syndrome
WANG He-yang
SU Xi
SHEN Cheng-xing
GUO Jin-cheng
WU Zhao-hui
ZHU Yong-hong
ZHAO Xin
LI Yi
HAN Ya-ling
Abstract：Objective To investigate the effectiveness and safety of ticagrelor in Chinese patients with acute coronary syndrome(ACS). Method ACS patients(n=1970) who received at least one dose of ticagrelor were chosen from Nov. 2011 to May. 2015. Baseline clinical characteristics, ticagrelor and other antiplatelet regimens and clinical events during follow up period were retrospectively analyzed. The estimated 2-year event rates of death, stroke and bleeding, as well as 2-year event-free survival rate were calculated with the Kaplan-Meier method. Results The mean age of all patients was (61.2±11.2) years. The proportion of unstable angina was 42.8%, non-ST segment elevation myocardial infarction was 20.6%and ST segment elevation myocardial infarctio was 36.6%. The average ticagrelor treatment time was (161.4±126.0) days. The patients were followed-up 0~784 days from discharge, with a median time of 195 (145,371) days. According to the Kaplan-Meier method, the estimated 2-year event rates of death, stroke and bleeding were 1.5%, 0.2% and 2.3%. The 2-year event-free survival rate was 96.1%. Conclusions Ticagrelor is associated with low rates of death, stroke and bleeding, suggesting a satisfied effectiveness and safety of ticagrelor in treating Chinese ACS patients. It needs further confirmation by large-scale randomized trials.
Keywords：TicagrelorAcute coronary syndromeEffectivenessSafety
Publication Date：2015-01-01